The European Medicines Agency’s (EMA) human medicines committee (CHMP) today announced recommendations for the approval of ...
French pharma major Sanofi (Euronext: SAN) today announced the discontinuation of clinical development of amlitelimab, an OX40-ligand monoclonal antibody, in moderate-to-severe atopic dermatitis (AD).
US pharma major Johnson & Johnson has reported positive top-line Phase III data showing that a dual bispecific antibody ...
A UK-headquartered clinical-stage biopharmaceutical company developing once-weekly oral GLP-1 and amylin analogs for obesity ...
Spanish medical dermatology company Almirall (BME: ALM) has reported first-half 2026 net sales of 602.7 million euros ($687.1 ...
A commercial-stage Chinese biopharmaceutical company pursuing BTK and TYK2 inhibition across oncology and autoimmune disease, ...
French ophthalmology specialist Théa has entered into a long-term manufacturing partnership with French CDMO Unither Pharmaceuticals to build a dedicated sterile eye care production facility in the ...
US RNA medicines company Arrowhead Pharmaceuticals (Nasdaq: ARWR) saw its shares rise about 19% after reporting positive top-line results from two pivotal Phase III studies of plozasiran in severe ...
A young California start-up wants to do for drug development what enterprise software did for accounting and sales: put the ...
UK gene therapy company EpilepsyGTx has named Teresa Nunes as its chief medical officer, tasking her with steering lead ...
USA-based gout specialist Crystalys Therapeutics has closed an oversubscribed $130 million series B financing to fund ...
Less than a month after a US advisory panel voted against it, AstraZeneca's (LSE: AZN) camizestrant has won a positive opinion from Europe's Committee for Medicinal Products for Human Use (CHMP), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results